← Leaderboards
Michael Berney
Albert Einstein College Of Medicine
$7,991,239
Attributed
$7,991,239
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,991,239 · 6
By mechanism
R01$6,618,667 · 3
R21$1,372,572 · 3
Top collaborators
No co-investigators on record.
Most similar at Albert Einstein College Of Medicine
Same institution · by research overlap
- William Robert Jacobs$47,063,631
- Michael Aschner$17,443,221
- Fajun James Yang$8,579,386
- Eliseo A Eugenin$12,967,403
- Onyinyechukwu Chioma Uchime$144,372
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMycobacterium TuberculosisIn VivoAntibioticsCellsIn VitroMetabolicInfectionCommunicable DiseasesTuberculosis DrugsDrug DiscoveryBacteriaDrug ResistanceAnimalsKnock-DownStructureDrug TargetingMouse ModelMycobacterialTuberculosisMutantPreventPropertyAntitubercular Agents
Grant awards (19)
Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling$636,812
R01 · FY2025 · AI · contact PI
The PDIM paradox of M. tuberculosis$501,801
R01 · FY2025 · AI · contact PI
Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling$636,812
R01 · FY2024 · AI · contact PI
The PDIM paradox of M. tuberculosis$501,801
R01 · FY2024 · AI · contact PI
Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling$653,812
R01 · FY2023 · AI · contact PI
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases$630,978
R01 · FY2023 · AI · contact PI
The PDIM paradox of M. tuberculosis$501,801
R01 · FY2023 · AI · contact PI
Coenzyme F420, helping mycobacteria find a niche in humans$198,000
R21 · FY2023 · AI · contact PI
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases$630,978
R01 · FY2022 · AI · contact PI
Coenzyme F420, helping mycobacteria find a niche in humans$253,400
R21 · FY2022 · AI · contact PI
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases$631,410
R01 · FY2021 · AI · contact PI
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases$632,476
R01 · FY2020 · AI · contact PI
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases$571,898
R01 · FY2019 · AI · contact PI
Rapid screening for modes-of-action of M. tuberculosis inhibitors by high-throughput metabolic fingerprinting$210,086
R21 · FY2019 · AI · contact PI
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases$88,088
R01 · FY2019 · AI · contact PI
Rapid screening for modes-of-action of M. tuberculosis inhibitors by high-throughput metabolic fingerprinting$165,215
R21 · FY2018 · AI · contact PI
Rapid screening for modes-of-action of M. tuberculosis inhibitors by high-throughput metabolic fingerprinting$86,621
R21 · FY2018 · AI · contact PI
Inhibition of methionine biosynthesis eliminates persistent M. tuberculosis.$208,750
R21 · FY2017 · AI · contact PI
Inhibition of methionine biosynthesis eliminates persistent M. tuberculosis.$250,500
R21 · FY2016 · AI · contact PI